Education

• PhD, Biopharmaceutics, 1985, State University of New York at Buffalo
  (Professor Gerhard Levy).
• MS Pharmaceutical Analysis and Chemistry, 1980, Leyden, The Netherlands and San Francisco (Professor Sidney Riegelman).

---

Areas of Interest

Pharmacodynamics of drugs for prostate and pancreatic cancer and pharmacokinetic approaches to understand and improve regional cancer therapy. Polymer-based slow release systems for regional drug administration. Mathematical modeling of biological processes.

---

Publications

Kosarek, C.E., Hu, X., Couto, C.G., Kisseberth, W.C., Green, E.M., Au, J.L., and Wientjes, M.G.  Phase I evaluation of low-dose suramin as chemosensitizer of doxorubicin in dogs with naturally occurring cancers.  J. Vet. Intern. Med., 20:1172-1177, 2006.

Chen, D., Song, S.H., Wientjes, M.G., Yeh, T.K., Villalona-Calero, M., Otterson, G., Jensen, R., Grever, M., Murgo, A., and Au, J.L.-S. Nontoxic suramin as a chemosensitizer in patients: Dosing nomogram development. Pharm. Res., 23:1265-1274, 2006.

Gan, Y., Walsh, C., Wientjes, M.G., and Au, J.L.-S. Expression of basic fibroblast growth factor correlates with resistance to paclitaxel in human tumors. Pharm. Res., 23:1324-1331, 2006.

Wientjes, M.G., Zheng, J.H., Hu, L., Gan, Y., and Au, J.L.-S.  Intraprostatic chemotherapy: Kinetics and mechanisms of doxorubicin transport. Clin. Cancer Res., 11:4204-4211, 2005.

Yeh, T.K., Lu, Z., Wientjes, M.G., and Au, J.L.-S.  Formulation of paclitaxel alters its disposition.  Pharm. Res, 22:867-874, 2005.

Bolanos-Meade, J., Jacobsohn, D.A., Margolis, J., Ogden, A., Wientjes, M.G., Byrd, J.C., Lucas, D.M., Anders, V., Phelps, M., Grever, M.R., and Vogelsang, G.B.  Pentostatin in steroid-refractory acute graft-versus-host disease.  J Clin. Oncol., 23:2661-2668, 2005.

Xin, Y., Song, S.H., Lyness, G., Chen, D., Jang, S., Wientjes, M.G., and Au, J.L.-S. Low-dose suramin as a chemosensitizer of bladder cancer to mitomycin C.  J Urol,  174:322-327, 2005.

Lu, Z., Yeh, T.K., Tsai, M., Au, J.L.-S., and Wientjes, M.G. Paclitaxel-loaded gelatin nanoparticles for intravesical bladder cancer therapy. Clin. Cancer Res., 10:7677-7684, 2004.

Ogden, A., Wientjes, M.G., and Au, J.L.-S. Suramin as a chemosensitizer: oral pharmacokinetics in rats. Pharm. Res., 21:2058-2063, 2004.

Song, S.H., Yu, B., Wei, Y., Wientjes, M.G. and Au, J. L.-S. Low-dose suramin enhanced paclitaxel activity in chemotherapy-naive and paclitaxel-pretreated human breast xenograft tumors. Clin. Cancer Res., 10:6058-6065, 2004.

Jang, S.H., Wientjes, M.G., Lu, D., and Au, J.L. Drug delivery and transport to solid tumors. Pharm. Res., 20:1337-1350, 2003.

Villalona-Calero, M., Wientjes, M.G., Otterson, G.A. Kanter, S. Young, D., Murgo, A.J., Fischer, B., DeHoff, Ca., Chen, D., Yeh, T.-K., Song, S-H., Grever, M., Au, J. L.-S. Phase I study of low dose suramin as a chemosensitizer in patients with advanced non-small cell lung cancer. Clin. Cancer Res., 9:3303-3311, 2003.

Johnston , J.S., Johnson, A., Gan, Y., Wientjes, M.G. and Au, J. L.-S. Synergy between 3’-azido-3’deoxythymidine and paclitaxel in human pharynx FaDu cells. Pharm. Res., 20:957-961, 2003.

Chen, D., Song, D., Wientjes, M.G. and Au, J. L.-S. Effect of dimethyl sulfoxide on bladder tissue penetration of intravesical paclitaxel. Clin. Cancer Res., 9:363-369, 2003.

Mo, Y., Gan, Y., Song, S.H., Johnston, J., Xiao, X., Wientjes, M. G., and Au, J. L.-S. Simultaneous targeting of telomere and telomerase as a cancer therapeutic approach. Cancer Res., 63:579-585, 2003.

Jang, S-H., Wientjes, M.G. and Au, J. L.-S. Interdependent effect of P-glycoprotein-mediated drug efflux and intracellular paclitaxel pharmacokinetics: application of computational modeling. JPET, 304:1-8, 2003.

Zhao, L., Wientjes, M.G., and Au, J.L.-S. Evaluation of combination chemotherapy: integration of nonlinear regression, curve shift, isobologram, and combination index analyses. Clin. Cancer Res., 10:7994-8004, 2004.

Li, D., Jang, S-H., Kim, J., Wientjes, M.G., and Au, J. L.-S. Enhanced drug-induced apoptosis associated with P-glycoprotein overexpression is specific to antimicrotubule agents. Pharm. Res., 20:45-50, 2003.

Gan,Y., Mo, Y., Johnston, J., Lu, J., Wientjes, M.G., Au, J.L.-S. Telomere maintenance in telomerase-positive human ovarian SKOV-3 cells cannot be retarded by complete inhibition of telomerase. FEBS Let., 527:10-14, 2002.

Au, J.L-S., Jang, S., and Wientjes, M.G. Clinical aspects of drug delivery to tumors. J. Controlled Release, 78:81-95, 2002.

Grecula, J.C., Schuller, D.E., Smith, R., Rhoades, C.A., Nag, S., Bauer, C.J., Agrawal, A., Au, J.L., Young, D., Gahbauer, R.A. Long-term follow-up on an intensified treatment regimen for advanced resectable head and neck squamous cell carcinomas. Cancer Invest, 19:127-136, 2001.

Zhang, Y., Song, A-H., Au, J.L.-S., and Wientjes, M.G. Nontoxic doses of suramin enhances activity of doxorubicin in prostate tumors. J. Pharmacol. Exper. Therap., 299:425-433, 2001.

Song, S-H., Wientjes, M.G., Walsh, C., and Au, J.L.-S. Nontoxic doses of suramin enhances activity of paclitaxel against lung metastasis. Cancer Res., 61:6145-6150, 2001.

Li, D., Gan, Y., Wientjes, M.G., and Au, J.L.-S. Distribution of DT-diaphorase and NADPH:cytochrome P450 reductase in bladder tissues and metastases. J. Urol. 166:2500-2505, 2001.

---

Courses Taught

Pharmacy 803: Disposition of Xenobiotics

Principles and practical considerations in the study of xenobiotic pharmacokinetics and metabolism; current research approaches and techniques.

---

Professional Experience

2002-present: Editor, PharmSci.

2002-2003: Chair, Experimental Therapeutics I study section, NCI, NIH.

1998-2002: Member, Experimental Therapeutics I study section, NCI, NIH.

1997: Ad hoc member, Experimental Therapeutics I study section, NCI, NIH.

1997: Member, Research Evaluation and Decision Panel, AIDS Malignancy Consortium, NCI, NIH.

1995. Member, Special Review Committee, Adult Clinical Trials Groups. NIAID, NIH.

1988-present: Member, OSU Comprehensive Cancer Center.

2000-present: Professor, College of Pharmacy, Division of Pharmaceutics, The Ohio State University at Columbus, OH.

1994-2000: Associate Professor, College of Pharmacy, Division of Pharmaceutics, The Ohio State University at Columbus, OH.

1994-1998: Associate Professor, Department of Surgery, Division of Urology, The Ohio State University at Columbus, OH.

1992-1994: Assistant Professor, College of Pharmacy, Division of Pharmaceutics, The Ohio State University at Columbus, OH.

1988-1994: Assistant Professor, Department Of Surgery, Division of Urology, The Ohio State University at Columbus, OH.

1986-1988: Research Scientist, Department of Pharmacology and Toxicology, Section of Chemical Safety and Drug Development, Battelle Memorial Institute, Columbus Division, Columbus, OH.

1984-1986: Assistant Professor, College of Pharmacy, Division of Pharmaceutics and Pharmaceutical Chemistry and School of Medicine, Department of Hematology and Oncology, The Ohio State University, Columbus, OH, Member, OSU Comprehensive Cancer Center.

---